CIK 0002007919 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | |
|---|---|---|
| Revenue (USD) | 1.3 M | 1.8 M |
| Net income (USD) | -140.1 M | -241.4 M |
| Diluted EPS (USD/shares) | -9.04 | -20.48 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-14 | 4 | FORM 4 | 2026-10-14 |
| 2026-09-28 | 4 | FORM 4 | 2026-09-25 |
| 2026-09-28 | 8-K | 8-K items 7.01,9.01 | 2026-09-28 |
| 2026-09-23 | 4 | FORM 4 | 2026-09-23 |
| 2026-09-18 | 4/A | FORM 4/A | 2026-06-03 |
| 2026-09-18 | 4/A | FORM 4/A | 2026-06-03 |
| 2026-09-18 | 4/A | FORM 4/A | 2026-06-03 |
| 2026-09-18 | 4/A | FORM 4/A | 2026-06-03 |
| 2026-09-17 | 4 | FORM 4 | 2026-09-16 |
| 2026-09-15 | 4 | FORM 4 | 2026-09-11 |
| 2026-09-15 | 144 | 144 | |
| 2026-09-14 | 144 | 144 | |
| 2026-09-11 | 144 | 144 | |
| 2026-09-10 | 4 | FORM 4 | 2026-09-08 |
| 2026-09-09 | 144 | 144 | |
| 2026-09-08 | 144 | 144 | |
| 2026-09-08 | 4 | FORM 4 | 2026-09-08 |
| 2026-09-08 | 4 | FORM 4 | 2026-09-08 |
| 2026-09-08 | 4 | FORM 4 | 2026-09-08 |
| 2026-09-08 | 8-K | 8-K items 7.01,8.01,9.01 | 2026-09-08 |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-14 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-13 | 8-K | 8-K items 2.02,9.01 | 2026-08-13 |
| 2026-08-13 | 10-Q | 10-Q | 2026-06-30 |
Forms on file (last 1,000): 4 45, 8-K 27, 424B3 11, 3 10, 10-Q 7, SCHEDULE 13G/A 6, 144 5, SCHEDULE 13G 5. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=INBX (0.002 USD), /gw/filings/filings?ticker=INBX&form=8-K, /gw/filings/facts?ticker=INBX&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange